Skip to main content
. 2024 Aug 21;9(9):103677. doi: 10.1016/j.esmoop.2024.103677

Figure 1.

Figure 1

Progression-free survival (PFS) and overall survival (OS) according to primary tumor sidedness and sex in BRAFmt metastatic colorectal cancer (mCRC). (A) PFS according to primary tumor sidedness in BRAFmt mCRC. (B) OS according to primary tumor sidedness in BRAFmt mCRC. (C) PFS in male patients with BRAFmt mCRC according to primary tumor sidedness. (D) OS in male patients with BRAFmt mCRC primary tumor sidedness. (E) PFS in female patients with BRAFmt mCRC according to primary tumor sidedness. (F) OS in female patients with BRAFmt mCRC according to primary tumor sidedness. P values correspond to Cox regression. BRAFmt, BRAFV600E mutant/RAS wild-type; CI, confidence interval; HR, hazard ratio; OS, overall survival; PT, primary tumor.